Organisation paid for research Program year 2025 Source: CMS Open Payments

Uro Associates Admn

Neither a doctor nor a teaching hospital

Research payments

$189,955

46 payments

Through program year 2025, Uro Associates Admn is reported as receiving $189,955 in research payments, across 46 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$6,979	15
2024	Research	$30,392	12
2023	Research	$54,358	9
2022	Research	$76,732	7
2021	Research	$21,494	3

Breakdown

Who paid Research payments · program years 2021–2025

Janssen Research & Development, LLC $189,955 46 payments

Studies the money was for Research payments · program years 2021–2025

A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy $81,823 22 payments
17000139Blc2002 $62,838 9 payments
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical C $21,494 3 payments
A Phase 3 Randomized Placebo controlled Double blind Study of JNJ56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy naive Metastatic Castration resistant Prostate Cancer mCRPC $17,216 1 payment
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) $4,527 3 payments
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC $2,057 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.